We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sponsors of Cancer Vaccines Face Unique Challenges
Sponsors of Cancer Vaccines Face Unique Challenges
September 30, 2009
Clinical trial sponsors testing vaccines to treat cancer should consider enrolling patients with little or no evidence of the disease because they are more likely to survive long enough to develop an anti-tumor immune response, as opposed to the conventional models that study patients with advanced metastatic disease, a new FDA draft guidance says.